| 糖尿病治疗的新希望——SGLT2抑制剂 |
| |
| 引用本文： | 李莹,钱海,黄文龙. 糖尿病治疗的新希望——SGLT2抑制剂[J]. 中国新药杂志, 2011, 0(21) |
| |
| 作者姓名： | 李莹 钱海 黄文龙 |
| |
| 作者单位： | 中国药科大学新药研究中心; |
| |
| 基金项目： | 国家自然科学基金(81172932) |
| |
| 摘 要： | 钠依赖的葡萄糖运载体(SGLTs)是一类在小肠黏膜和肾近曲小管中发现的转运基因家族,肾脏重吸收葡萄糖的过程主要由SGLTs介导。其中,SGLT1和SGLT2最为重要,SGLT2起主导作用。选择性地抑制SGLT2能显著降低机体对葡萄糖的重吸收,通过增加尿糖的排出从而降低血糖水平。SGLT2抑制剂是一种创造性的治疗策略,其作用靶点和机制与现有降糖药均不同,成为降糖药物研究的热点。文中介绍了SGLT2在调节血糖平衡中的作用,简单介绍了部分在研SGLT2抑制剂,重点综述了Ⅲ期临床药物dapagliflozin的临床试验结果。
|
| 关 键 词： | 糖尿病 SGLT2抑制剂 构效关系 dapagliflozin 研究进展 临床试验 |
SGLT2 inhibitors:a new therapy for diabetes |
| |
| LI Ying,QIAN Hai,HUANG Wen-long. SGLT2 inhibitors:a new therapy for diabetes[J]. Chinese Journal of New Drugs, 2011, 0(21) |
| |
| Authors: | LI Ying QIAN Hai HUANG Wen-long |
| |
| Affiliation: | LI Ying,QIAN Hai,HUANG Wen-long(Center of Drug Discovery,China Pharmacutical University,Nanjing 210009,China) |
| |
| Abstract: | Sodium-glucose co-transporters(SGLTs) are a family of transporters found in the intestinal mucosa of small intestine and the proximal tubule of the nephron.They(especially SGLT1 and SGLT2) contribute to renal glucose reabsorption.SGLT2 plays more important role than SGLT1.Selective inhibition of SGLT2 is an innovative therapeutic strategy for the treatment of diabetes by enhancing glucose loss through the urine.The mechanism of action is different from the currently diabetes medications.In this review,we pr... |
| |
| Keywords: | diabetes SGLT2 inhibitors structure-activity relationship dapagliflozin development research clinical trial |
| 本文献已被 CNKI 等数据库收录！ |
|
